One of the most important advances in biology has been the discovery that siRNA (small
interfering RNA) is able to regulate the expression of genes, by a phenomenon known as …

Abstract Recently, United States Food and Drug Administration (FDA) and European
Commission (EC) approved Alnylam Pharmaceuticals' RNA interference (RNAi) therapeutic …

Background: The molecular mechanism of tumorigenesis remains to be fully understood in
breast cancer. It is urgently required to identify genes that are associated with breast cancer …

Cancer often develops multidrug resistance (MDR) when cancer cells become resistant to
numerous structurally and functionally different chemotherapeutic agents. MDR is …

Breast cancer (BC) is amongst the most lethal cancer among females and conventional
treatment methods like surgery, radiotherapy and chemotherapy are not effective enough as …

Within the tumor microenvironment (TME), regulatory T cells (Tregs) play a key role in
suppressing anticancer immune responses; therefore, various strategies targeting Tregs are …

Gene silencing via RNA interference (RNAi) is rapidly evolving as a personalized approach
to cancer treatment. The effector molecules—small interfering RNAs (siRNAs) and …

Triple negative breast cancer (TNBC) and non-small cell lung cancer (NSCLC) are amongst
the most aggressive forms of solid tumors. TNBC is highlighted by absence of genetic …

Triple negative breast cancer (TNBC) is a subtype of breast cancer characterized by
absence of estrogen (ER) receptor, progesterone (PR) receptor, and human epidermal …

Breast cancer is the most frequently diagnosed cancer among women. Breast cancer is also
the key reason for worldwide cancer-related deaths among women. The application of small …